Compare Adobe Systems Inc (ADBE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs 10X Genomics Inc — how do they compare? Adobe Systems Inc trades at $220.46 (market cap $88.06B), while 10X Genomics Inc trades at $35.65 (market cap $4.80B). The key difference: Adobe Systems Inc is far larger — about 18.3× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | TXG | |
|---|---|---|
Market Cap | $88.06B | $4.80B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $40.00 |
52-Week Low | $193.41 | $11.34 |
Enterprise Value | $89.50B | $4.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $219.75, up 0.77% with strong fundamentals including 29.99% net margin and consistent earnings beats. The stock shows bullish technical signals despite recent volatility, with support at $218 and resistance at $228. Revenue growth accelerated to $23.77B in 2025, while institutional activity remains mixed amid AI competition concerns.
ADBE presents a compelling value opportunity with a 12.67 P/E ratio and 49% analyst buy ratings, though AI disruption fears and CEO transition create near-term uncertainty. The consensus price target of $246.75 implies 12% upside potential, balanced against sector-wide software pressures.
TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.
The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
